

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

**Enzo Biochem, Inc.**

---

(Name of Registrant as Specified in Its Charter)

---

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

---

---

(2) Aggregate number of securities to which transaction applies:

---

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

---

---

(4) Proposed maximum aggregate value of transaction:

---

---

(5) Total fee paid:

---

---

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:

---

---

(2) Form, Schedule or Registration Statement No.:

---

---

(3) Filing Party:

---

---

(4) Date Filed:

---

---



# Investor Presentation

---

January 2020

---



---

# Disclaimer

The views expressed in this presentation (this "Presentation") represent the opinion of Enzo Biochem, Inc. (the "Company"). This Presentation is for informational purposes only, and it does not have regard to the specific investment objective, financial situations, suitability or particular need of any specific person who may receive this Presentation and should not be taken as advice on the merits of any investment decision. This Presentation is not a recommendation or solicitation to buy or sell any securities of the Company.

The Company has not sought or obtained consent from any third party to use any statements or information indicated in this Presentation as having been obtained or derived from a third party. Any such statements or information should not be viewed as indicating the support of such third party for the views expressed in this Presentation. Information contained in this Presentation has not been independently verified by the Company, and the Company disclaims any and all liability as to the completeness or accuracy of the information and for any omissions of material facts. The Company disclaims any obligation to correct, update or revise this Presentation or to otherwise provide any additional materials.

The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from shareholders in connection with the Company's 2019 Annual Meeting of Shareholders. Information regarding the direct and indirect interests, by security holdings or otherwise of the Company's participants is set forth in the Company's definitive proxy statement and proxy supplement for the 2019 Annual Meeting of Shareholders filed with the SEC on December 5, 2019 and December 31, 2019, respectively. The Company's definitive proxy statement and proxy supplement can be found on the SEC's website at [www.sec.gov](http://www.sec.gov) or the Company's website at <http://www.enzo.com/corporate/investor-information>.

Except for historical information, the matters discussed in this Presentation may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues and expenses, which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigation and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2019. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this Presentation.

## Situation Overview

- Harbert Discovery Fund ("Harbert")—a short-term oriented activist hedge fund focused on micro-cap companies that we believe has no operational experience or background in our sector—is seeking to replace two highly qualified directors up for election at Enzo's 2019 Annual Meeting **and take control of 40% of Enzo's Board**
- Over a period of several months, Enzo made concerted efforts to engage constructively with Harbert and understand their perspectives, but **our efforts to work constructively with Harbert were not reciprocated**
  - Enzo met with Harbert and provided a "Lab Tour" in January 2019
  - In May 2019, Harbert demanded that we immediately replace two incumbent directors (with no preference as to which incumbents it wanted to resign) without disclosing to us the names of their proposed replacement candidates until July 2019
  - In an effort to engage constructively with Harbert, Enzo waived its request for the D&O questionnaire to be completed; **Harbert never responded to our invitation to interview their candidates**
  - In addition to not following standard, reasonable protocol for director nominations, **Harbert has not demonstrated knowledge of our business or sector or advanced a coherent plan to improve Enzo**
- While Harbert has attacked us, **Enzo has a history of proactive change to our business and corporate governance profile**, informed by active engagement with our shareholders
  - Exploration of strategic alternatives for Therapeutics business with the assistance of Lazard
  - Implemented initiatives to reduce costs in light of industry environment
  - Recent Board addition, Rebecca Fischer, resulting from thoughtful refreshment process, and adoption of Board Diversity Policy
  - Governance enhancements such as bylaw proposed for adoption of majority voting and modifications to compensation plan to increase alignment with long-term performance
  - Appointment of new CFO to free Barry Weiner up to focus on operations and ensure that the CFO is no longer a Board member



## Situation Overview (cont'd)

- **Enzo's strategy is the product of extensive analysis and thoughtful planning and is showing meaningful progress**
  - Our business plan is well-vetted and deliberate; in contrast, we believe **Harbert's ill-conceived arguments demonstrate an utter lack of understanding of our business** and of the challenges facing the broader diagnostics market and **do not create long-term value for Enzo shareholders**
  - Harbert has not made any suggestions to improve the business that Enzo's Board has not already thoroughly considered
- Enzo's candidates have **deep expertise and knowledge of our business and sector** and are the right choice to continue Enzo's progress on its value-creation strategy
  - By contrast, Harbert's nominees do not have relevant experience for Enzo and, moreover, repeatedly refused to share any insights or plan for Enzo
  - The only public company directorship ever held by either candidate is at a micro-cap company based in Georgia (former Soviet Republic)

**At this critical juncture, replacing two highly qualified candidates with Harbert's highly questionable nominees should raise significant concerns for shareholders**

# The Board Has Made the Necessary Changes to Position Enzo for Success

## Evolution of Business and Strategy

- ✓ Innovator, disruptor and groundbreaking pioneer in modern biological research
- ✓ Thoughtful and well-considered transition to a fully integrated healthcare company
- ✓ Business model and operational structure thoughtfully designed to capitalize on industry headwinds and offer unique value proposition to reduce costs by 30–50%<sup>1</sup>
- ✓ Execution of recently announced three-pronged strategy for value creation
- ✓ Exploration of strategic alternatives for Therapeutics business
- ✓ Implemented initiatives to reduce costs in light of industry environment

## Evolution of Leadership and Governance

- ✓ Recent addition of new Director, Rebecca Fischer, following robust, proactive search process
- ✓ Recent announcement of new CFO appointment and separation of President and CFO functions
- ✓ Recent corporate governance enhancements, including proposed bylaw for adoption of majority voting standard for uncontested elections
- ✓ Compensation program that is responsive to shareholder feedback and aligned with performance
- ✓ Highly qualified nominees with valuable expertise and knowledge of Enzo's business and our sector



# Enzo's Market Opportunity Is Substantial

By continuing to execute its three-pronged strategy for value creation, Enzo is poised to capitalize on significant market opportunity

## Total Addressable Molecular Diagnostics Market (\$ million, 2019E)

Diagnostic Assay	North America	Global
Infectious Diseases	\$1,500	\$3,300
Womens Health	\$700	\$1,300
CT/NG	\$300	\$450
BV	\$140	\$300
HPV	\$300	\$430
HSV	\$90	\$250
HIV	\$160	\$363
HBV	\$250	\$561
HCV	\$120	\$264
<b>Total</b>	<b>\$3,560</b>	<b>\$7,218</b>
<b>Enzo's Current Market Share</b>		
		<1.0%
<b>Revenue from Incremental 1% Market Share</b>	<b>\$36</b>	<b>\$72</b>
<b>Potential Enzo Revenue Impact<sup>1</sup></b>	<b>44%</b>	<b>89%</b>

## Additional Market Opportunities

- Enzo's opportunity in molecular diagnostics is significant, with each incremental 1% of global market share corresponding to \$72m of incremental revenue
  - And, molecular diagnostics is just one portion of Enzo's overall diagnostics offering
- Enzo is also executing to expand its share of the ~\$170bn clinical lab market



### How Is Enzo Capitalizing on the Opportunity?

Enzo is executing its three-pronged strategy for value creation to take advantage of significant opportunities across its businesses



Harbert threatens to jeopardize Enzo's strategy at exactly the wrong time

Source: Grand View Research, Public Company Reports.  
1 Relative to FY19 Revenue of \$81m.

# Executing Three-Pronged Strategy for Value Creation

Enzo is making meaningful progress in executing its three-pronged strategy designed to unlock shareholder value and drive future growth

## Progress

<b>Form Strategic Relationships for Diagnostic Growth</b>	<ul style="list-style-type: none"><li>• Actively engaging with several global life sciences, healthcare and medical device companies</li><li>• Seeking to form strategic relationships or new venture creation across key product platforms</li><li>• Retained Lazard to assist in forming strategic relationships or new venture creation</li></ul>
<b>Build a New Model for the Diagnostic Marketplace</b>	<ul style="list-style-type: none"><li>• Rolled out new Labs-to-Labs business model, whereby Enzo will serve as the "central capability" for smaller and mid-size labs, thereby increasing capacity utilization and profitability<ul style="list-style-type: none"><li>– Initiated first three Labs-to-Labs relationships and actively forging additional relationships</li></ul></li><li>• Capitalizing on scale in high-value, lower-cost operations, proprietary IP and products, decades of innovation and commitment to medical solutions</li></ul>
<b>Return to Operating Profitability and Growth in the Lab Segment</b>	<ul style="list-style-type: none"><li>• Aggressively controlling operational costs and improving margins in the labs segment to return labs business to growth and profitability</li><li>• Implemented initiatives estimated to reduce routine expenses in labs by ~\$10 million in the coming calendar year</li><li>• Objective remains to return to operating profitability in calendar 2020</li></ul>

"We continue to believe that Enzo's strategy to be a low cost provider of diagnostic products and services—"central capability" for smaller labs—should resonate, and it appears Enzo is progressing towards having a critical mass on the product side to engage in a fuller rollout of the strategy"

Craig-Hallum Capital Group Research Report  
June 2019

## Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo

- × Harbert refused to engage in constructive discussions with Enzo, including initially refusing to provide the identities of their nominees; Harbert's nominees have declined to participate in a standard nominee interview process
- × Neither Harbert nor its nominees have presented a coherent strategy or plan for Enzo other than driving a fire sale of Enzo at depressed valuations
- × Harbert's nominees lack any relevant experience and offer no discernable additive value to Enzo's Board of Directors and if elected, would comprise 40% of Enzo's Board
- × Harbert has no investment track record in the healthcare space (as historical activist positions have been in the Finance and Technology sectors) and is a relatively new shareholder in Enzo
- × Harbert's critiques of Enzo are uninformed and demonstrate a fundamental lack of knowledge about our business and sector
- × Flawed investment thesis jeopardizes Enzo's meaningful progress at a critical time
- × Harbert has an alleged criminal history in New York, whereas Enzo has close relationships with regulators in New York and has created jobs and provided vital services in the state

*Harbert has failed to suggest a single idea to improve Enzo's business that the Board has not already thoughtfully considered*

# What Is Harbert Hiding?

We believe Harbert's disingenuous behavior and lack of healthcare experience raise alarming questions about their intentions

1

*Refusal to Participate  
in Board  
Refreshment Process*

Harbert refused to identify their nominees for months and later declined our invitation to interview their candidates

2

*Lack of Healthcare  
Experience*

Harbert has no experience with investments in healthcare

3

*Unqualified and  
Inferior Nominees*

Harbert's nominees have no relevant healthcare experience or public Board experience and are far less qualified than the Company's nominees

*Harbert's lack of cooperation, healthcare knowledge and thoughtful ideas for Enzo are highly disconcerting*

---

The Choice for Shareholders Is Clear:  
Vote for Enzo's Nominees on the  
WHITE Card

## Table of Contents

	Page
<b>Enzo's Business, Strategy and Progress</b>	12
<b>Our Qualified, Engaged Board of Directors</b>	31
<b>Harbert and Its Nominees Lack Relevant Experience</b>	38
<b>Harbert's Unfounded Critiques of Enzo</b>	45
<b>Our Recommendation to Shareholders</b>	56



---

## **Enzo's Business, Strategy and Progress**

Our Qualified, Engaged Board of Directors

Harbert and Its Nominees Lack Relevant Experience

Harbert's Unfounded Critiques of Enzo


Our Recommendation to Shareholders

# Snapshot of Enzo

Enzo's unique, vertically integrated and self-funded novel diagnostics model has resulted in a track record of innovation

<b>\$81m in FY19 Revenue</b> <b>\$130m Market Cap<sup>1</sup></b>	<b>Robust Licensing Program</b> <b>Generating \$154m in</b> <b>Income since 2011<sup>2</sup></b>	<b>Self-Funded</b> <b>R&amp;D</b>
<b>500 Employees across</b> <b>8 Commercial Locations</b>	<b>\$1.3bn<sup>3</sup> in Revenue Derived</b> <b>from IP Commercialization</b> <b>to Date</b>	<b>400+ Patents Awarded in</b> <b>Total; 74 in 2019 Alone</b>

## Enzo's Recent Comparative Performance: 5 Years<sup>4</sup>



1 As of 1/3/2020.  
 2 FY2011 – FY2019.  
 3 Based on Company estimates.  
 4 5 year TSR calculated going back to 4/8/2014, five years prior to the date of Harbert's 13D filing.  
 5 Proxy peers include: ARRY, FLDM, HBIO, LMNX, MACK, MNTA, NEO, NSTG, OSUR, OXFD, PACB, QDEL, ROEN, SPPJ and VIVO. NTRA, NVTA excluded due to recent IPDs subsequent to 4/8/2014.



# Overview of Enzo's Business

**Enzo has evolved into a new model for a modern diagnostics company, with a unique and strategic vertical integration that positions Enzo to capitalize upon ongoing pressures in the diagnostics market place**

- 1 Enzo is the new model for a modern diagnostics company, with a unique and synergistic vertical integration model that fuels Enzo's value creation**
  - Enzo's diagnostics, clinical services and innovation and IP technology platforms are interdependent and allow Enzo to deliver 30–50%<sup>1</sup> cost savings to customers based on current market prices
- 2 Enzo is well-positioned to succeed in spite of recent industry headwinds**
  - Declining reimbursement and increasing costs are sector-wide headwinds but create opportunities for Enzo's unique cost savings proposition
- 3 Enzo is actively executing its three-pronged strategy for value creation and making progress**
- 4 Enzo's track record of innovation and disruption continues today and enables a highly profitable IP strategy**
- 5 Enzo's robust and experienced management team provides thoughtful, experienced and engaged leadership**

# 1 Enzo's Unique Novel Diagnostics Model Is Comprehensive and Delivers Savings

Enzo's open system platform delivers solutions that align with diagnostics workflow and enable 30–50%<sup>1</sup> cost savings

## Diagnostics Workflow




## Diagnostics Segments



1 Based on Company estimates.

# 1 Enzo's Vertical Integration Strength


Under the leadership of an engaged management team and Board, Enzo has developed into a uniquely integrated novel diagnostics company



**Unique vertical integration is the product of extensive strategic planning and enables innovation/disruption, cost savings and operational flexibility**

# 1 Enzo's Three Interdependent Businesses


Enzo's integrated model houses synergistic and symbiotic businesses that enhance the overall value of the combined company



The critical synergies between Enzo's interdependent businesses mean that any separation would destroy meaningful value


# 1 While Enzo's Novel Diagnostics Structure and Resources Are Complete and Integrated...

Enzo's novel diagnostics model positions the company to manage costs while investing in technological innovation and create a platform that is fully automated, high capacity, low cost and broad menu



# 1 ...the Rest of the Molecular Diagnostics Market Remains Incomplete and Fragmented

Other market participants have been unable to vertically integrate and cannot respond to reimbursement pressure like Enzo





## 2 Enzo is Well-Positioned to Succeed Despite Recent Industry Headwinds

**In the past five years, Enzo has laid the foundation for a pioneering model for a novel diagnostics business that effectively responds to cost pressures faced by clinical labs**


- Industry dynamics impose severe, increasing pressure on lab margins
  - Declining reimbursement
  - Unreasonably high cost of goods sold (COGS) for high volume tests imposed by reliance on “closed” diagnostics systems that inhibit third-party reagent competition
- Enzo identified the opportunity created by industry headwinds and responded by pursuing a strategy to transform into an integrated healthcare company in 2015
- Initial traction in 2017, as headwinds from reimbursement and COGS accelerated
  - PAMA law signing announced in 2014, effective January 2018
  - Further validated the long-term case for Enzo’s business model, despite short-term challenges

“While reimbursement is a persistent pressure point... **we do believe it to be an affirmation**—though it will take time to manifest—of Enzo’s push to lower the cost of diagnostic products and services... We think **its economic case as a lab-to-lab product and service provider will increasingly resonate**, as we think it highly improbable that other labs (of all sizes) aren’t dealing with similar pressures. Ultimately, we think **that pressure plays into Enzo’s strategy and, eventually, will show up in results.**”

CRAIG HALLUM CAPITAL GROUP RESEARCH REPORT, OCTOBER 2018

**As the market adapts to the reimbursement environment, Enzo is well positioned to succeed**

## 2 Enzo's Cost Savings Proposition Creates a Unique Market Opportunity



### Independent Clinical Labs Face Amplified Pressure Following PAMA:

"Back in 2016-2017, both Lab-Corp and Quest Diagnostics had the foresight to lock down nearly all of their private insurance contracts at pre-PAMA rates for multi-year contract lengths. This has helped them limit the fallout from PAMA to mostly just their Medicare and Medicaid fee-for-service revenues. But most independent clinical labs were unable to lock in pre-PAMA rates for their private insurance contracts."

LABORATORY ECONOMICS VOLUME 14 NO. 12, DECEMBER 2019

"It was tough pre-2018 and with the PAMA pricing pressure, it's become even tougher. Frankly, I'm amazed that so many independent labs have been able to hang on... How are smaller labs making money? I imagine they're working hard and not sleeping well... they have got to diversify into... some form of proprietary testing that is shielded from PAMA."

LABORATORY ECONOMICS VOLUME 14 NO. 9, SEPTEMBER 2019



## 2 Enzo's Unique Value Proposition to Customers

### **Potential Savings:**

- Cumulative royalty relief—Enzo owns ALL IPs **+10–15%**
  - *IP generation process is already paid for*
- Low cost of goods **+10–20%**
  - *Enzo's cumulative technology capability is the foundation*
  - *Enzo's robust product development pipeline creates platforms with low cost of product development for open systems*
- No capital investment **+10–15%**
  - *Enzo's products don't require dedicated/expensive/closed systems instrumentation*

---

**Estimated Total Savings:** **30–50%**

---

**Even with reimbursement erosion, we deliver cost relief to the market while maintaining healthy margins for Enzo**


## 2 Why Haven't Other Players Addressed the Problem?

Others in the industry have not been able to adapt to today's reimbursement pressures, creating opportunity for Enzo to disrupt the antiquated single-platform-centric model



### Maxed Out Effort in Reducing Costs

- Clinical labs have made substantial efforts to reduce costs and focus on labor expenses
  - Due to business- and operations-mandated staffing levels, clinical labs are **no longer able to continue to cut labor** costs as aggressively as in the past
  - Cost of referring molecular diagnostics tests to other clinical labs is prohibitive, and cost of reagents is proportionate to reimbursement pressure



### Molecular Diagnostics Are Unable or Unwilling to Reduce Prices

- In many clinical labs, the costs of the reagents utilized to run diagnostics tests are greater than the amount payors are paying
  - Closed systems molecular diagnostics platforms companies have generally refused or have been unable to reduce the prices they charge to clinical labs due to margin pressure
- Closed systems complete the margin squeeze
  - Legacy diagnostics manufacturers need closed systems to force reagents to single-test platforms, i.e., test kits that generally only work on the instrumentation with which they were sold

### 3 Executing Three-Pronged Strategy for Value Creation

Enzo is making meaningful progress in executing its three-pronged strategy designed to unlock shareholder value and drive future growth

Progress

<p><b>Form Strategic Relationships for Diagnostic Growth</b></p>	<ul style="list-style-type: none"> <li>• Actively engaging with several global life sciences, healthcare and medical device companies</li> <li>• Seeking to form strategic relationships or new venture creation across key product platforms</li> <li>• Retained Lazard to assist in forming strategic relationships or new venture creation</li> </ul>
<p><b>Build a New Model for the Diagnostic Marketplace</b></p>	<ul style="list-style-type: none"> <li>• Rolled out new Labs-to-Labs business model, whereby Enzo will serve as the "central capability" for smaller and mid-size labs, thereby increasing capacity utilization and profitability             <ul style="list-style-type: none"> <li>– Initiated first three Labs-to-Labs relationships and actively forging additional relationships</li> </ul> </li> <li>• Capitalizing on scale in high-value, lower-cost operations, proprietary IP and products, decades of innovation and commitment to medical solutions</li> </ul>
<p><b>Return to Operating Profitability and Growth in the Lab Segment</b></p>	<ul style="list-style-type: none"> <li>• Aggressively controlling operational costs and improving margins in the labs segment to return labs business to growth and profitability</li> <li>• Implemented initiatives estimated to reduce routine expenses in labs by ~\$10 million in the coming calendar year</li> <li>• Objective remains to return to operating profitability in calendar 2020</li> </ul>

"We continue to believe that Enzo's strategy to be a low cost provider of diagnostic products and services—"central capability" for smaller labs—should resonate, and it appears Enzo is progressing towards having a critical mass on the product side to engage in a fuller rollout of the strategy"

Craig-Hallum Capital Group Research Report  
June 2019

### 3 Recent Strategic Highlights


**Unlocking Value in Therapeutics Subsidiary**

- ✓ Considering various avenues, including spin-off, sale, joint venture or licensing to unlock value
- ✓ Determination to explore alternatives takes account of significant capital requirements necessary to:
  - Fully recognize the Therapeutics subsidiary's value today
  - Address the opportunities for further validation
  - Provide necessary funding and focus to drive commercialization

**Expanding Good Manufacturing Practices Facilities**

- ✓ Completed construction of new Good Manufacturing Practices facility, extending Farmingdale campus to nearly 101,000 ft<sup>2</sup>
- ✓ Expands capacity to manufacture routine and specialty products and components
- ✓ Expands capacity to store inventory



### 3 Enzo's Product and Development Wins in 2019

Recent achievements show that Enzo is delivering meaningful progress and on-track to deliver more

#### 2019 Highlights and Announcements

Jan.–Feb.	> Entered into a settlement agreement with Roche Diagnostics and Roche Molecular Systems
Mar.–May	> Entered into a state licensing agreement with Hologic and Grifols Diagnostic Solutions to settle all outstanding patent disputes amongst the parties, including one-time payments totaling \$14m to Enzo
Jun.–Jul.	> Announced issuance of United States patent for treatment of liver cancer using Ozanimod
Aug.–Sep.	> Announced key transformative diagnostic initiatives to propel and accelerate growth in the business including: New York State Health Department's approval of oral and rectal STI testing, creation of direct-to-consumer testing business for STIs and development of new model for Labs-to-Labs diagnostic testing business > Announced issuance of United States patent for Advanced Nucleic Acid Hybridization Probe Technology for clinical and research applications, advancing the Company's ability to offer lower-cost high-performance products and services in the clinical diagnostics market
Oct.–Dec.	> New York State Health Department approved Hepatitis B Virus Quantitative Clinical Assay, AmpiProbe > Approval of AmpiProbe HBV viral load assay represents milestone in providing comprehensive menu of molecular diagnostics tests for sexually transmitted infections > Over 2019, Enzo ran over 100,000 Lab Development Tests, resulting in estimated cost savings of \$5 million

Recent achievements indicate Enzo is on track to deliver meaningful progress



### 3 Enzo's Market Opportunity Is Substantial

By continuing to execute its three-pronged strategy for value creation, Enzo is poised to capitalize on significant market opportunity

**Total Addressable Molecular Diagnostics Market (\$ million, 2019E)**

Diagnostic Assay	North America	Global
Infectious Diseases	\$1,500	\$3,300
Womens Health	\$700	\$1,300
CT/NG	\$300	\$450
BV	\$140	\$300
HPV	\$300	\$430
HSV	\$90	\$250
HIV	\$160	\$363
HBV	\$250	\$561
HCV	\$120	\$264
<b>Total</b>	<b>\$3,560</b>	<b>\$7,218</b>
<b>Enzo's Current Market Share</b>		
		<1.0%
<b>Revenue from Incremental 1% Market Share</b>	<b>\$36</b>	<b>\$72</b>
<b>Potential Enzo Revenue Impact<sup>1</sup></b>	<b>44%</b>	<b>89%</b>

**Additional Market Opportunities**

- Enzo's opportunity in molecular diagnostics is significant, with each incremental 1% of global market share corresponding to \$72m of incremental revenue
  - And, molecular diagnostics is just one portion of Enzo's overall diagnostics offering
- Enzo is also executing to expand its share of the ~\$170bn clinical lab market



**How Is Enzo Capitalizing on the Opportunity?**

*Enzo is executing its three-pronged strategy for value creation to take advantage of significant opportunities across its businesses*



**Harbert threatens to jeopardize Enzo's strategy at exactly the wrong time**


Source: Grand View Research, Public Company Reports.  
1 Relative to FY19 Revenue of \$81m.





## 4 Enzo Has a Legacy of Groundbreaking Innovation


Enzo's track record of industry disruption and strategic reinvention positions us for success



Enzo's continuous innovation over the past 40+ years has resulted in a robust IP portfolio that continues to drive value for all shareholders

## 4 Continued Commitment to Self-Funded R&D and a Profitable Licensing Strategy

Enzo has an extensive IP portfolio, which has meaningfully expanded over the past decade



- ✓ **Enzo continues to build its strong IP portfolio**
  - 74 patents awarded in 2019 alone
  - 400+ patents awarded in total
  - ~18% CAGR in total patent portfolio since 2011
- ✓ **IP has generated shareholders over a billion dollars in commercialization revenue<sup>1</sup>**

- ✓ **R&D and IP have been entirely self-funded without recourse to capital markets and dilution to shareholders**
- ✓ **Shareholders relay appreciation for Enzo's successful licensing program and recognize the economic benefit to the Company**

**While larger competitors continue to infringe on Enzo's IP, Enzo has aggressively and successfully defended its patents, resulting in \$154m in awards and licensing fees and demonstrating the significant value of Enzo's patent portfolio**

<sup>1</sup> Based on Company estimates.

## 5 Enzo's Strong, Experienced Management Team



**Dr. Elazar Rabbani**  
Co-Founder, CEO & Chairman

- ✓ Co-founder of Enzo Biochem
- ✓ Extensive, relevant experience in molecular biology
- ✓ Inventor of multiple, pioneering Enzo 400+ patents
- ✓ Published 40+ scientific publications on molecular biology



**Barry Weiner**  
Co-Founder, President & Executive Director

- ✓ Co-founder of Enzo Biochem
- ✓ Extensive, relevant industry and operational experience
- ✓ Business development, strategic and financial expertise
- ✓ Previously held managerial and marketing positions at Colgate Palmolive Company
- ✓ Member of the New York Biotechnology Association
- ✓ M.B.A. from Boston University



**David Bench**  
CFO

- ✓ Extensive relevant experience in diagnostics and healthcare technology
- ✓ Previously CFO of ELLKAY
- ✓ Previously held multiple investment banking positions across multiple firms
- ✓ Long career in day-to-day financial management and oversight
- ✓ Masters in International Finance from Brandeis University



**Dr. Dieter Schapfel**  
Chief Medical Director, Clinical Labs & VP Medical Affairs (Enzo Biochem, Inc.)

- ✓ Extensive, relevant experience in pathology
- ✓ Previously Medical Director of Pathology at Southside Hospital-North Shore/Long Island Jewish Health System
- ✓ Diplomate of the American Board of Pathology with certification in Anatomic and Clinical Pathology
- ✓ Diplomate of The National Board of Medical Examiners
- ✓ M.D. from State University of New York at Stony Brook, College of Medicine



**Kara Cannon**  
Chief Commercialization Officer, Global (Enzo Biochem, Inc.)

- ✓ Extensive, relevant experience in strategic and tactical marketing
- ✓ Previously held executive positions at Pall Corporation, focusing on the commercial operations within the areas of diagnostics, biotechnology, biosciences

---

Enzo's Business, Strategy and Progress

**Our Qualified, Engaged Board of Directors**

Harbert and Its Nominees Lack Relevant Experience

Harbert's Unfounded Critiques of Enzo

Our Recommendation to Shareholders

# Overview of Enzo's Board of Directors

Our current Board provides effective oversight and is best suited to drive Enzo's strategy



**Elazar Rabbani** ✓  
*Co-Founder, Chairman and CEO*  
 Lead Inventor and Named Patent Holder in 400+ Patents | Published Scientist in Molecular Biology



**Dr. Bruce Hanna** ✓  
*Independent Director, Nominating/Governance Committee Chair*  
 Clinical Professor of Pathology and Microbiology at NYU School of Medicine | Adjunct Professor of Basic Science at NYU College of Dentistry

Appointed as of December 31, 2019



**Rebecca Fischer** ✓  
*Independent Director, Audit Committee Chair*  
 CFO at Bellevue Hospital Center

- ✓ In-depth knowledge of relevant reimbursement and insurance environments
- ✓ Contributes to overall diversity of Enzo's Board
- ✓ Relevant operational and productivity enhancement knowledge
- ✓ Financial reporting, revenue enhancement and cost control expertise



**Dov Perlysky** ✓  
*Lead Independent Director, Compensation Committee Chair*  
 Managing Member at Nasher | Director at Pharma-Bio Serv

Resigned as of December 31, 2019

**Gregory Bortz** ✓  
*Independent Director*  
 Founder and Managing Partner at CREO Group | Chartered Accountant



**Barry Weiner** ✓  
*Co-Founder, President and Executive Director*  
 Former CFO | Unmatched Operational, Strategic and Financial Expertise for Enzo's Specific Business

Rebecca Fischer was appointed as a new independent Director effective as of December 31, 2019 following an extensive search process conducted as part of Enzo's ongoing focus on Board refreshment, composition and diversity. Gregory Bortz concurrently resigned from the Board.

## Barry Weiner

★ **Up for Reelection at  
2019 Annual Meeting**



**Barry Weiner**  
*Co-Founder & President*

- ✓ President and Director and a co-founder of Enzo Biochem
- ✓ Committed to Enzo: has served as the Company's President since 1996 and previously held the position of Chief Financial Officer and Executive Vice President
- ✓ Operational, strategic and financial expertise from serving at Enzo
- ✓ Meaningful investment in Enzo: owns 2.4% of the Company's shares outstanding
- ✓ Managerial and marketing experience at the Colgate Palmolive Company
- ✓ Member of the New York Biotechnology Association
- ✓ Bachelor of Arts degree in Economics from New York University
- ✓ Masters of Business Administration in Finance from Boston University

### Contributions to Enzo

- ✓ **Unmatched knowledge of Enzo's operating businesses, Innovation and IP Technology Platform, Diagnostics and Clinical Services, each of which present unique focuses and goals**
- ✓ **Demonstrated ability to execute Enzo's strategy, develop unparalleled innovation and fund the Company's growth without dilution of shareholders**
- ✓ **Manages a transparent and open investor relations program, feedback from which has resulted in enhancements to compensation program and corporate governance practices**
- ✓ **Effectively institutes governance reforms**

## Dr. Bruce Hanna, Ph.D.

★ **Up for Reelection at  
2019 Annual Meeting**



**Dr. Bruce Hanna**  
*Director*

- ✓ Director since January 2017 (3-year tenure; most recently added Director until Rebecca Fischer's appointment)
- ✓ Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine, Adjunct Professor of Basic Science at New York University College of Dentistry
- ✓ Former Adjunct Professor of Biology at Long Island University, served on the ASM International Committee and WHO Global Committee (2006–2015), Editor of Clinical Microbiology Reviews (2000-2012), Director of Clinical Microbiology, Immunology (1982–2008) at Bellevue Hospital Center, was Interim Director of Pathology (2008–2010) at Bellevue Hospital Center, Owner and Director at The Village Diagnostic Laboratory (1987–1999)
- ✓ Bachelor of Science in Biology from Saint Bonaventure University
- ✓ Masters of Science in Microbiology from Northeastern University
- ✓ Ph.D. in Microbiology from Saint John's University; Dr. Hanna's post-doctorate work in Clinical Microbiology was at Mt. Sinai Hospital

### Contributions to Enzo

- ✓ Appointed following a thoughtful and robust search process that specifically sought experience in diagnostics and clinical innovation
- ✓ Serves on the Audit, Nominating and Corporate Governance (Chairman) and the Compensation Committees
- ✓ Contributes extensive, relevant medical experience
- ✓ Integrally involved in the development of Enzo's strategy, operational progress, governance reform and shareholder engagement



# Recently Announced Board Refreshment

On December 31, 2019, following a robust, proactive search process, Enzo added Rebecca Fischer to the Board

★ *Up for Election at 2019 Annual Meeting*



**Rebecca Fischer**  
*Director*

- ✓ Chief Financial Officer at New York Health & Hospitals/Bellevue Hospital Center in New York City
- ✓ Addition followed a deliberate and thoughtful refreshment process that sought out particular skills
- ✓ Operational, revenue enhancement, reimbursement and insurance/payer experience from serving as CFO and other executive roles at Bellevue Hospital
- ✓ Senior Planning Associate at New York Presbyterian Hospital prior to joining Bellevue Hospital
- ✓ Previous experience includes progressively responsible positions at Columbia University Medical Center, the Center for State Health Policy at Rutgers University and the New York City Office of Management and Budget
- ✓ Bachelor of Arts in History and Government from Cornell University
- ✓ Masters of Public Administration in Health Policy and Management from New York University

## Contributions to Enzo

- ✓ **In-depth knowledge of policy making and relevant reimbursement and insurance environments**
- ✓ **Highly experienced in enacting policy and dealing with regulations in the healthcare industry**
- ✓ **Contributes to overall diversity of Enzo's Board**
- ✓ **Relevant operational and productivity enhancement knowledge**
- ✓ **Financial reporting, revenue enhancement and cost control expertise**




# Board Values Feedback Received from Multi-Year Engagement Program on Board, Governance and Compensation Matters

## Feedback integrated into Board's decision-making process

	Engagements and Improvements
2015	<ul style="list-style-type: none"><li>&gt; 55% Say-on-Pay result led to initiation of a robust shareholder engagement process</li></ul>
2016	<ul style="list-style-type: none"><li>&gt; Enzo engaged with top owners collectively accounting for ~50% of shares outstanding</li><li>&gt; Investors supported the executive compensation program generally, but noted the non-equity-based compensation was low compared to peers</li></ul>
2017	<ul style="list-style-type: none"><li>&gt; Enzo engaged with top owners collectively accounting for ~50% of shares outstanding</li><li>&gt; Following shareholder engagement efforts, Enzo decided to include performance-vested equity for fiscal 2018 that along with stock options could over time comprise up to 50% of long-term incentive grant value for NEOs</li></ul>
2018	<ul style="list-style-type: none"><li>&gt; Enzo engaged with top owners collectively accounting for ~60% of shares outstanding</li><li>&gt; Shareholders voiced their appreciation of the changes made to Enzo's compensation program, resulting in 86% support on Enzo's Say-on-Pay vote</li><li>&gt; Discussions with shareholders became more focused on Board and governance matters rather than on compensation</li></ul>
2019	<ul style="list-style-type: none"><li>&gt; Enzo engaged with top owners collectively accounting for over 60% of shares outstanding</li><li>&gt; In 2019, the Board's ongoing refreshment effort intensified, resulting in the recent appointment of Rebecca Fischer</li><li>&gt; The Board solicited additional shareholder feedback and thoughtfully considered its Board and governance</li><li>&gt; Enzo attempted to include Harbert's nominees in this process, but Harbert initially refused to provide their identities and later declined to permit their nominees to be interviewed</li><li>&gt; In response to feedback received, Enzo strengthened its governance practices by increasing the robustness of its Lead Independent Director's responsibilities and putting forth a proposal to adopt a majority voting standard</li></ul>

## Appointment of Ms. Fischer Is the Result of a Robust, Proactive Search Process

Rebecca Fischer's appointment followed a thoughtful Board refreshment process; Harbert refused to participate in this process



---

Enzo's Business, Strategy and Progress

Our Qualified, Engaged Board of Directors

**Harbert and Its Nominees Lack Relevant Experience**

Harbert's Unfounded Critiques of Enzo

Our Recommendation to Shareholders

## What Is Harbert Hiding?

We believe Harbert's disingenuous behavior and lack of healthcare experience raise alarming questions about their intentions

1

*Refusal to Participate  
in Board  
Refreshment Process*

Harbert refused to identify their nominees for months and later declined our invitation to interview their candidates

2

*Lack of Healthcare  
Experience*

Harbert has no experience with investments in healthcare

3

*Unqualified and  
Inferior Nominees*


Harbert's nominees have no relevant healthcare experience or public Board experience and are far less qualified than the Company's nominees

*Harbert's lack of cooperation, healthcare knowledge and thoughtful ideas for Enzo are highly disconcerting*

# Harbert's Inexperience in Healthcare Is Troubling

It is not surprising that Harbert admitted to not understanding the laboratory business, given they have no investment history other than Enzo in the healthcare sector

Harbert's Portfolio Composition over the Course of Its Activist History Illustrates a Total Lack of Healthcare Expertise



Harbert's Kenan Lucas admitted to having no knowledge of the laboratory business. This makes sense given Harbert has not held any activist holdings in the healthcare sector aside from Enzo:

<b>Antech Systems, Inc.</b> (Media & Telecom)	<b>BLUEROCK RESIDENTIAL</b> (Real Estate)	<b>Marchex</b> (Tech)	<b>ecology and environment, inc.</b> (Finance)	<b>LINN PROPERTY HOLDINGS</b> (Finance)
<b>Streamline Health</b> (Tech)	<b>KEY</b> Technology (Tech)	<b>QUMU</b> (Tech)	<b>iCAD</b> (Tech)	<b>perceptron</b> (Tech)

Source: FactSet

## Harbert's Problematic History in New York

Maintaining close and good relationships with regulators and elected officials in New York is vital to Enzo's business; by contrast, Harbert has an alleged history of deliberately skirting the rules in New York

"The New York attorney general's office on Tuesday said **it reached a \$40 million settlement with an Alabama investment firm** over the failure of members of an investment management company it sponsored to pay millions in New York state taxes [...]"

"Our investigation uncovered a brazen and deliberate decision to avoid paying millions in taxes owed to New York State," Mr. Schneiderman said in a statement. "**Harbert Management made a clear choice to skirt the rules, and as a result, ordinary New York taxpayers were left footing the bill.**"

THE WALL STREET JOURNAL, 18 APRIL 2017

## Harbert's Nominees Do Not Offer Value for Enzo

Because **Harbert's nominees declined to participate in any interview process, we have no basis for evaluating them** except based on their resumes



**Fabian Blank**



**Peter Clemens, IV**

*Uncooperative, Uninterested, Irrelevant*

**Harbert's nominees' resumes show they are not the right Directors for Enzo**

# Harbert Nominee: Fabian Blank

## Fabian Blank's hyper-regional and irrelevant experience is not additive to Enzo's Board



**Fabian Blank**

Only public board that either of Harbert's nominees serve on

- ✗ Employment history is hyper-regional and non-U.S. (Georgia (former Soviet Republic), Israel and Germany), of questionable value to Enzo and complicates Board participation
- ✗ According to his resume, he has at least 7 current affiliations—how can he devote the time required to be an effective Enzo Director?
- ✗ Declined invitation to be interviewed by Enzo's Board
- ✗ Experience disclosed in resume (our sole basis for evaluating him) is not relevant to Enzo
- ✗ Only public Board seat held is at micro-cap company in Georgia (former Soviet Republic)

Experience	Relevant to Enzo?	Why Irrelevant?
2019-Present Advisory Board Member at GYANT.COM	✗	AI-based virtual care
2018-Present Advisor to Georgia Healthcare Group	✗	Small hospital and pharmacy company in former Soviet Republic
2018-Present Senior Industry Advisor at Marconi Capital	✗	Capital raising and advisory boutique, focused on platform rollups
2018-Present Global Operating Partner; Head of Healthcare at Bamboo Capital Partners	✗	Commercial private equity investor focused on emerging markets
2016-Present Non-Executive Chairman at Recover Health	✗	Israeli-German digital health start-up
2015-Present Co-Founder of Vivira Health Lab	✗	German family-owned orthopedic rehab
2015-Present CEO of Meduna Klinik Group	✗	German company focused on rehab in the internal medicine, orthopedics and rheumatology fields



# Harbert Nominee: Peter Clemens, IV

**Peter Clemens leaves behind a trail of litigation from his prior roles and has no public company directorship experience**



**Peter Clemens, IV**

- ✗ Has not served on any public company Boards
- ✗ Experience disclosed in resume (our sole basis for evaluating him) is not relevant to Enzo
- ✗ Named defendant in litigation alleging that, while at Caremark, he received backdated stock options and then accepted CVS's bid because the merger structure would eliminate liability from the backdating scheme
- ✗ Claims to have worked with private equity to sell DSI Renal, a transaction being challenged as an asset dilution scheme in bankruptcy court
- ✗ Declined invitation to be interviewed by Enzo's Board

Experience		Relevant to Enzo?	Why Irrelevant?
2016–Present	Serves on the Board of Virturo Health	✗	Private prostate care provider company
2011–2017	Multiple positions at Surgical Care Affiliates	✗	Provider of outpatient surgery, based in Illinois
2010–2011	Served on the Board of DSI Renal	✗	Private dialysis company that went bankrupt
1995–2010	Multiple positions at CVS/Caremark	✗	Prescription benefit management subsidiary of CVS Health

---

Enzo's Business, Strategy and Progress

Our Qualified, Engaged Board of Directors

Harbert and Its Nominees Lack Relevant Experience

**Harbert's Unfounded Critiques of Enzo**

Our Recommendation to Shareholders

---

**“Harbert doesn’t know anything about the laboratory business” – Kenan Lucas, Harbert Portfolio Manager, 5/7/2019**

# Board Has Evaluated Harbert's Ideas → Remaining Claims Are Untruthful

## Harbert Claim

- A** ✘ Enzo should conduct a "full exploration of strategic alternatives, with a focus on potential sales of non-core assets and intellectual property"
- B** ✘ Enzo has not delivered on Ampiprobe technology potential or strategic partnerships
- C** ✘ Enzo lacks the scale/expertise for the "labs-to-labs" business model to succeed
- D** ✘ Enzo's IP has not produced returns
- E** ✘ Enzo's compensation is excessive, misaligned and unjustifiable
- F** ✘ Enzo's governance benefits insiders at the expense of other stakeholders
- G** ✘ Harbert's nominees are highly qualified candidates, who will represent and act in the best interests of Enzo shareholders

## Reality

- ✓
  - Enzo has announced an exploration of strategic alternatives for its Therapeutics business
  - The remaining Labs, Diagnostic and IP businesses are interdependent and more valuable together than separated
- ✓
  - Enzo has expanded Ampiprobe technology's scalability and applications, and Enzo has executed over one hundred licensing and supply deals and is in discussions with potential partners
- ✓
  - Enzo has made progress and is well-positioned to execute on the "labs-to-labs" strategy
  - Enzo has capitalized on multiple commercial opportunities for its Labs business
- ✓
  - Enzo has generated over \$1.3bn<sup>1</sup> in revenue derived from IP commercialization to date
  - Enzo has received \$154m in awards and licensing fees vs. spending only \$45m in litigation expenses since 2011
- ✓
  - CEO compensation is lowest among peer group
  - Compensation program is informed by shareholder feedback and received recent strong support from proxy advisory firms and shareholders
- ✓
  - Recent Board refreshment and enhancements of governance practices are directly responsive to shareholder feedback
- ✓
  - Harbert's nominees do not have any relevant experience to serve on Enzo's Board

<sup>1</sup> Based on Company estimates.

**A Harbert Claim: Enzo should conduct a full exploration of strategic alternatives**  
**Reality: Enzo is already committed to active portfolio management and a break-up of the business would entail meaningful dis-synergies**

**Unlocking Value in Therapeutics Subsidiary**

- ✓ Considering various avenues, including spin-off, sale, joint venture or licensing to unlock value
- ✓ Determination to explore alternatives takes account of significant capital requirements necessary to:
  - Fully recognize the Therapeutics subsidiary's value today
  - Address the opportunities for further validation
  - Provide necessary funding and focus to drive commercialization

**Separating Enzo's Remaining Businesses Would Create Dis-synergies**

- ✓ Now is not the right time to separate Enzo's remaining businesses given reimbursement pressures, efficiency savings being realized and a return to profitability
- ✓ There remains significant opportunity in the diagnostics market and consequently, little value would be ascribed as an independent entity today
- ✓ The integrated model is a deliberate combination of synergistic and symbiotic businesses that drive meaningful growth opportunities for Enzo as a whole
- ✓ In forming this thoughtful and comprehensive strategy, Enzo's Board considered the panoply of alternatives – including the break-up value of the stand-alone businesses – and concluded the integrated model best positions Enzo to maximize value for all shareholders
- ✓ IP is unlikely to be fully valued in a separation and is best leveraged through a vertically integrated business

**B** Harbert Claim: Enzo has not delivered on Ampiprobe technology potential or strategic partnerships

**Reality: Enzo is actively engaged in discussions with potential partners and has meaningfully expanded Ampiprobe technology's scalability and applications**

- ✓ Developed Ampiprobe technology to increase scalability and broaden dimensions and applications
- ✓ Meaningful revenue of Ampiprobe-related systems expected within 12 months post-national rollout
- ✓ Attained New York State Regulatory Approval on 8 different analytes already being delivered from our lab and working on rolling out high throughput, fully automated system
- ✓ Enzo has signed over one hundred licensing deals with leading global companies
- ✓ Retained Lazard to assist with forming strategic relationships

**C** Harbert Claim: Enzo lacks the scale/expertise for the “labs-to-labs” business model to succeed

***Reality: Enzo has made progress and is well-positioned to execute on the “labs-to-labs” strategy, recently capitalizing on multiple commercial opportunities for its Labs business***


- ✓ Formalized three Labs-to-Labs relationships and actively negotiating terms with other small- to medium-sized clinical labs
- ✓ ~50% expansion in personnel supporting commercialization
- ✓ Ran over 100,000 Enzo laboratory developed tests resulting in more than \$5 million in year-over-year cost savings compared to third-party vendor tests

**D Harbert Claim: Enzo's IP has not produced returns**  
**Reality: Enzo has generated over \$1.3bn<sup>1</sup> in revenue derived from IP commercialization to date**

Enzo's legal settlements far outweigh legal costs by a factor of more than 3x



■ Litigation Settlements and Royalties  
 ■ Total Legal Expenditures



**Enzo's innovative IP portfolio Enzo has generated over \$1.3bn<sup>1</sup> in product sales, distribution and licensing fees to date**

<sup>1</sup> Based on Company estimates.  
<sup>2</sup> Includes all legal expenses as reported.




**E** Harbert Claim: Enzo's compensation is excessive, misaligned and unjustifiable  
**Reality: CEO compensation is lowest among peer group**

A comparison of Enzo's CEO compensation relative to peers reveals it is entirely appropriate

Harbert: "Since 2004... the Board approved paying chairman/CEO Elazar Rabbani and his brother-in-law CFO Barry Weiner over \$34 million, including a bonus every single year."

However, based on a recent timeline and relevant peer set, Enzo's CEO pay is the lowest of our peers and our recent Say-on-Pay has received high shareholder support




**E Harbert Claim: Enzo's compensation is excessive, misaligned and unjustifiable**  
**Reality: Compensation program is informed by feedback over multiple years of shareholder engagement and has received strong shareholder support**

**Enzo's Executive Compensation program is structured to appropriately align management's interests with those of shareholders and vetted by compensation consultant Gallagher**

Components of Compensation	
Component	Metrics
<b>Base Salary</b> (Cash)	<ul style="list-style-type: none"> <li>Reviewed annually</li> </ul>
<b>Non-Equity Incentive Compensation</b> (At-Risk Cash)	<ul style="list-style-type: none"> <li>30%-60% Financial Performance Measures</li> <li>20%-30% Strategic and Operational Performance Measures</li> <li>30% Individual Performance Measures</li> </ul>
<b>Long-Term Incentives</b> (Stock Options, RSUs, PSUs)	<ul style="list-style-type: none"> <li>Three-year Revenue growth</li> <li>Three-year Adjusted EBITDA growth</li> </ul>

Compensation Metrics Tied to Long-Term Strategy
<b>Link to Strategy</b>
<ul style="list-style-type: none"> <li>Among other things, attract, retain and motivate the best possible executives capable of driving achievement of the Company's strategic objectives</li> <li>Each performance metric is consistent with our core operating performance and focus on driving strong business improvement in fiscal 2018-2019</li> <li>Provide strong link to long-term performance, create an ownership culture and align management interests with those of shareholders</li> <li>Serve as both a reward for contributing to Enzo's success and an incentive for future performance</li> </ul>



**Recent Enhancements**

**Performance-Vested Equity added in Fiscal 2018:**

Although we do not observe use of a performance-vested equity mechanism to a significant degree among our peers, this enhancement was driven by feedback received from shareholders, internal research and the consideration of our independent compensation consultant, Gallagher, to further align compensation with shareholder interests and promote accountability.

<sup>1</sup> In 2018, other NEOs included Barry W. Weiner, James M. O'Brien, Dieter Schapfel, Kara Cannon and Bruce A. Dey.



**F Harbert Claim: Enzo's governance benefits insiders at the expense of other stakeholders**  
**Reality: Recent Board refreshment and enhancements to governance practices are directly responsive to shareholder feedback**

4+-year-old engagement program in Board, governance and compensation matters informs Board decisions

✓ **Thorough, Proactive Refreshment Process**

- ✓ Refreshments are handled by the Nominating and Governance Committee
- ✓ Proactively reviews Board candidates to determine eligibility and contributions to Enzo's Board
- ✓ Considers nominations from shareholders
- ✓ To holistically approach refreshment, candidates submit a questionnaire and interview with the Committee, and later the whole Board
- ✓ Recently announced the appointment of Rebecca Fischer, CFO of Bellevue Hospital, who contributes meaningful experience in relevant regulatory and reimbursement environments and contributes to the Board's overall diversity profile

✓ **Stronger Lead Independent Director Role**

- ✓ Bolstered Lead Independent Director's responsibilities
- ✓ Solely responsible for approving Board meeting agendas and schedules
- ✓ Positioned as liaison for shareholders and designated contact between shareholders and other interested persons, if requested

✓ **Separation of CFO and President**

- ✓ Appointment of new CFO to free Barry Weiner up to focus on operations and ensure that the CFO is no longer a Board member

✓ **Diversity Policy**

- ✓ In response to **shareholder feedback received via Enzo's proactive engagement process**, Enzo established a diversity policy that undeniably cements diversity's importance and benefits in the Company's governance

✓ **Majority Voting Proposal**

- ✓ In response to **shareholder feedback received via Enzo's proactive engagement process**, Enzo is proposing bylaw for a majority voting standard, to be voted on at the upcoming 2019 Annual Meeting
- ✓ Modernizes Enzo's governance to be more amenable to shareholders

**Enzo's governance framework is appropriately tailored to its specific situation and highly responsive to shareholder feedback; nonetheless, the framework remains in-line with peers and industry benchmark**

**G** Harbert's Claim: Harbert's nominees are highly qualified candidates  
**Reality: Harbert's candidates have no direct relevant experience for Enzo**



**Fabian Blank**

**Hyper-regional and irrelevant experience is not additive to Enzo's Board**

- ✗ Employment history is hyper-regional and non-U.S. (Georgia (former Soviet Republic), Israel and Germany), of questionable value to Enzo and complicates Board participation
- ✗ According to his resume, he has at least 7 current affiliations—how can he devote the time required to be an effective Enzo Director?
- ✗ Declined invitation to be interviewed by Enzo's Board
- ✗ Experience disclosed in resume (our sole basis for evaluating him) is not relevant to Enzo
- ✗ Only public Board seat held is at micro-cap company in Georgia (former Soviet Republic)



**Peter Clemens, IV**

**No public company directorship experience and leaves behind a trail of litigation from his prior roles**

- ✗ Has not served on any public company Boards
- ✗ Experience disclosed in resume (our sole basis for evaluating him) is not relevant to Enzo
- ✗ Named defendant in litigation alleging that, while at Caremark, he received backdated stock options and then accepted CVS's bid because the merger structure would eliminate liability from the backdating scheme
- ✗ Claims to have worked with private equity to sell DSI Renal, a transaction being challenged as an asset dilution scheme in bankruptcy court
- ✗ Declined invitation to be interviewed by Enzo's Board

---

**Enzo's Business, Strategy and Progress**

**Our Qualified, Engaged Board of Directors**

**Harbert and Its Nominees Lack Relevant Experience**

**Harbert's Unfounded Critiques of Enzo**

**Our Recommendation to Shareholders**

# The Board Has Made the Necessary Changes to Position Enzo for Success

## Evolution of Business and Strategy

- ✓ Innovator, disruptor and groundbreaking pioneer in modern biological research
- ✓ Thoughtful and well-considered transition to a fully integrated healthcare company
- ✓ Business model and operational structure thoughtfully designed to capitalize on industry headwinds and offer unique value proposition to reduce costs by 30–50%<sup>1</sup>
- ✓ Execution of recently announced three-pronged strategy for value creation
- ✓ Exploration of strategic alternatives for Therapeutics business
- ✓ Implemented initiatives to reduce costs in light of industry environment

## Evolution of Leadership and Governance

- ✓ Recent addition of new Director, Rebecca Fischer, following robust, proactive search process
- ✓ Recent announcement of new CFO appointment and separation of President and CFO functions
- ✓ Recent corporate governance enhancements, including proposed bylaw for adoption of majority voting standard for uncontested elections
- ✓ Compensation program that is responsive to shareholder feedback and aligned with performance
- ✓ Highly qualified nominees with valuable expertise and knowledge of Enzo's business and our sector



## Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo

- × Harbert refused to engage in constructive discussions with Enzo, including initially refusing to provide the identities of their nominees; Harbert's nominees have declined to participate in a standard nominee interview process
- × Neither Harbert nor its nominees have presented a coherent strategy or plan for Enzo other than driving a fire sale of Enzo at depressed valuations
- × Harbert's nominees lack any relevant experience and offer no discernable additive value to Enzo's Board of Directors and if elected, would comprise 40% of Enzo's Board
- × Harbert has no investment track record in the healthcare space (as historical activist positions have been in the Finance and Technology sectors) and is a relatively new shareholder in Enzo
- × Harbert's critiques of Enzo are uninformed and demonstrate a fundamental lack of knowledge about our business and sector
- × Flawed investment thesis jeopardizes Enzo's meaningful progress at a critical time
- × Harbert has an alleged criminal history in New York, whereas Enzo has close relationships with regulators in New York and has created jobs and provided vital services in the state

*Harbert has failed to suggest a single idea to improve Enzo's business that the Board has not already thoughtfully considered*



## Enzo's Nominees Are the Clear Choice



Barry Weiner



Dr. Bruce Hanna

- ✓ Demonstrated ability to execute strategy, develop unmatched innovation and fund the Company's growth without dilution of shareholders
- ✓ Contribute extensive, relevant medical experience
- ✓ Integrally involved in the development of Enzo's strategy, operational progress, governance reform and shareholder engagement
- ✓ Skin in the game means alignment with all shareholders



Fabian Blank



Peter Clemens, IV

- × Experience not relevant or additive to Enzo's Board
- × Declined opportunity to participate in standard interview process, suggesting disinterest in serving on our Board
- × Likely to promote Harbert's short-term objective of driving a fire sale at depressed valuations
- × If elected, would control 40% of Enzo's Board



---

The Choice for Shareholders Is Clear:  
Vote for Enzo's Nominees on the  
WHITE Card

Questions? Need Help Voting?  
Please contact our Strategic Shareholder Advisor and Proxy Solicitation  
Agent,  
Kingsdale Advisors

CONTACT US:



Kingsdale Advisors  
1-888-518-1554 (toll-free in North America)  
416-867-2272 (outside of North America)  
email: [ENZ@kingsdaleadvisors.com](mailto:ENZ@kingsdaleadvisors.com)